{
    "clinical_study": {
        "@rank": "119542", 
        "brief_summary": {
            "textblock": "This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2\n      (PLA2) inhibitor, in the treatment of chronic plaque psoriasis.  Antiflammin-2 in an\n      ointment base, or the vehicle alone will each be applied four times per day to a single\n      plaque in a randomized, double-blinded fashion."
        }, 
        "brief_title": "A Pilot Study of Topical Antiflammin-2 for Psoriasis", 
        "completion_date": "December 2000", 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "This study is a pilot trial designed to evaluate topical antiflammin-2, a phospholipase A2\n      (PLA2) inhibitor, in the treatment of chronic plaque psoriasis.  Antiflammin-2 in an\n      ointment base, or the vehicle alone will each be applied four times per day to a single\n      plaque in a randomized, double-blinded fashion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients must be age 18 or older.\n\n        Patients male or female must use contraception if of childbearing age.  No men and women\n        actively attempting to conceive a child during the time of drug testing.  No pregnant or\n        nursing women.\n\n        Patients must be otherwise healthy, immunocompetent, ambulatory patients with psoriasis\n        who have more than 5 percent of their body surface area involved with the disease or who\n        have localized disabling psoriasis.\n\n        Have failed one prior topical treatment regimen including topical cortiscosteroids, coat\n        tar preparations, or ultraviolet light.\n\n        An ambulatory performance status of 0,1,2 (ECOG Scale).\n\n        Ability to participate in an out -patient study and to provide informed consent.\n\n        Creatinine less than 2.0 mg/100ml.  Bilirubin less than or equal to 1.5 mg/100ml;\n        prothrombin time less than or equal to 1.3 times control.  WBC greater than 3000/mm(3),\n        granulocytes greater than  1500/mm(3), platelets greater than 100,000/mm(3).\n\n        No clinically significant cardiac disease.\n\n        No patients with previously documented serious infectious diseases such as pneumocystis\n        pneumonia, mycobacterium avium infection, etc. which would suggest clinically evident\n        immunodeficiency.\n\n        No systemic treatment for psoriasis (methotrexate, PUVA, UVB, cyclosporine, etc.) and\n        topical treatments (corticosteroids, tar, anthralin, etc.) during the four weeks prior to\n        study entry, and topical treatment during the two weeks prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001371", 
            "org_study_id": "940048", 
            "secondary_id": "94-C-0048"
        }, 
        "keyword": [
            "Inflammation", 
            "Lipocortin", 
            "Phospholipase A-2", 
            "Skin", 
            "Uteroglobin", 
            "Psoriasis"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Pilot Study of Topical Antiflammin-2 for Psoriasis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001371"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1993", 
        "study_design": "N/A", 
        "study_type": "Observational", 
        "verification_date": "December 1999"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}